Bank Julius Baer & Co
TPTX

Bank Julius Baer & Co’s Turning Point Therapeutics, Inc. Common Stock TPTX Stock Holding History

Bank Julius Baer & Co’s Portfolio TPTX Stock Details TPTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-10,425
Closed -$986K – 889
2021
Q1 		$986K Buy
+10,425
New +$1.24M 0.01% 347

Other funds holding TPTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Bank Julius Baer & Co's TPTX Position: Q2 2021 in Review

Bank Julius Baer & Co sold out of Turning Point Therapeutics, Inc. Common Stock (TPTX) in Q2 2021, closing a stake of 10,425 shares — an estimated $986K sold.

Bank Julius Baer & Co first reported a position in TPTX in Q1 2021 and held it in 1 quarter. The position peaked at $986K in Q1 2021. 190 funds tracked by Wall St. Rank hold TPTX as of Q2 2021.

  • Bank Julius Baer & Co reported no remaining Turning Point Therapeutics, Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
  • Bank Julius Baer & Co sold 10,425 Turning Point Therapeutics, Inc. Common Stock shares in Q2 2021, an estimated $986K.
  • Bank Julius Baer & Co first reported a position in Turning Point Therapeutics, Inc. Common Stock in Q1 2021 and held it in 1 quarter.
  • Bank Julius Baer & Co's Turning Point Therapeutics, Inc. Common Stock position peaked at $986K in Q1 2021.
  • 190 funds tracked by Wall St. Rank held Turning Point Therapeutics, Inc. Common Stock as of Q2 2021.

Based on Bank Julius Baer & Co's 13F filing for Q2 2021, filed 23 Jul 2021.